Navigation Links
Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
Date:6/4/2008

LONDON and PHILADELPHIA, June 5 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the addition of Prous Science routes of synthesis (ROS) data to the Newport Horizon Premium and Newport Vision Premium solutions. An ROS focused search allows users to identify active pharmaceutical ingredients (APIs) according to an intermediate or reagent used, number of available routes or by patents referenced in a given route. Provided free of charge to current subscribers of the Premium systems, this new dataset, which provides an exciting compliment to the kilogram demand data released in March, enhances product targeting, business development and competitive intelligence by helping users to understand better the chemistry and manufacture of APIs.

The true or original manufacturing process used for a particular API is usually well protected by patents, making it challenging to devise equivalent, cheaper or more efficient processes without infringing on the originator's intellectual property. The new dataset will help to remedy this by providing extensive information for more than 2,500 APIs, consisting of:

-- Full chemical name

-- CAS number

-- Synthesis route diagram

-- Text commentary (with each step indexed to the diagram)

-- Patent references (linked to the patent page)

-- Intermediate chemicals and CAS numbers

-- Reagent chemicals and CAS numbers

-- Scientific journal references

"Understanding the 'recipe' of how a particular active ingredient is made -- or could be made -- is of vital importance to API manufacturers, generic companies and innovators," said Mike Chace-Ortiz, Senior Director, Product Strategy, Thomson Reuters. "By providing access to this important data, Newport Horizon Premium and Newport Vision Premium now allow our customers to gauge which patents are involved, what raw materials are needed, the cost and complexity of the process and whether specialized equipment or facilities must be bought or constructed."

For further information on Thomson Reuters API Intelligence solutions, visit: http://scientific.thomsonreuters.com/newport/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to http://www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
2. Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines
3. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
4. Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare
5. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
6. Thomson Healthcare Announces Enhancements to Order Sets Solution
7. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
8. Thomson Scientific Introduces a New Quarterly Report Identifying the Movers and Shakers in the U.S. Generics Industry
9. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
10. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: